PPLPHARMA

Piramal Pharma Limited entered the pharmaceutical industry in 1988 through the acquisition of Nicholas Laboratories. The company operates globally, offering end-to-end drug development and manufacturing solutions across several segments including Contract Development and Manufacturing Organisation (CDMO), Complex Hospital Generics (CHG), and consumer healthcare. Its products and services encompass comprehensive drug development and manufacturing solutions. Piramal Pharma serves markets in India, North America, the UK/Europe, and over 100 other countries. The company has expanded through mergers, acquisitions, and organic growth, maintaining 17 development and manufacturing facilities. Notable transactions include the sale of its Domestic formulations business to Abbott in 2010 for $3.7 billion and the sale of its Diagnostic Services to Super Religare Laboratories (SRL). Approximately 70% of its revenue comes from regulated markets.